|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009647,
umls-concept:C0010592,
umls-concept:C0013018,
umls-concept:C0025241,
umls-concept:C0030705,
umls-concept:C0033522,
umls-concept:C0040732,
umls-concept:C0059985,
umls-concept:C0199176,
umls-concept:C0209368,
umls-concept:C0376545,
umls-concept:C0445356
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2004-5-21
|
|
pubmed:abstractText |
In an attempt to decrease toxicity in high-risk patients undergoing unrelated donor hematopoietic stem cell transplantation (URD HSCT), we tested a combination of cyclosporine (CSP) and mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis with the reduced-intensity conditioning regimen fludarabine/melphalan (Flu/Mel). A total of 22 adult patients with advanced myeloid (n=15) and lymphoid (n=7) malignancies were treated. All patients received Flu 25 mg/m2 for 5 days and Mel 140 mg/m2, with CSP 3 mg/kg daily and MMF 15 mg/kg three times a day. The median age was 49 years (range 18-66). Durable engraftment was seen in all but one patient with myelofibrosis. The 1-year nonrelapse mortality was 32%, 27% from GVHD. The cumulative incidence of acute GVHD grade 2-4 and 3-4 was 63 and 41%, respectively. With a median follow-up of 18 months, the disease-free survival (DFS) and overall survival (OS) are 55 and 59%, respectively. For patients with AML and MDS (n=14), the DFS and OS is 71%. For patients undergoing a second transplant (n=14), the DFS and OS is 57%. In conclusion, this regimen is associated with acceptable toxicity but high rates of GVHD in high-risk patients undergoing URD HSCT. Encouraging disease control for patients with advanced myeloid malignancies was observed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
pubmed-author:Al-KadhimiZZ,
pubmed-author:AngelopoulouMM,
pubmed-author:CohenSS,
pubmed-author:ELOYRR,
pubmed-author:FalkP MPM,
pubmed-author:FormanS JSJ,
pubmed-author:KogutNN,
pubmed-author:KrishnanA YAY,
pubmed-author:NademaneeAA,
pubmed-author:O'DonnellM RMR,
pubmed-author:ParkerPP,
pubmed-author:PopplewellLL,
pubmed-author:RodriguezRR,
pubmed-author:SahebiFF,
pubmed-author:SchriberJJ,
pubmed-author:SenitzerDD,
pubmed-author:SlovakMM,
pubmed-author:SmithDD,
pubmed-author:SnyderD SDS,
pubmed-author:SomloGG,
pubmed-author:SpielbergerRR,
pubmed-author:SteinAA
|
|
pubmed:copyrightInfo |
Copyright 2004 Nature Publishing Group
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
33
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1123-9
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:15064696-Adolescent,
pubmed-meshheading:15064696-Adult,
pubmed-meshheading:15064696-Aged,
pubmed-meshheading:15064696-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15064696-Cyclosporine,
pubmed-meshheading:15064696-Female,
pubmed-meshheading:15064696-Graft Survival,
pubmed-meshheading:15064696-Graft vs Host Disease,
pubmed-meshheading:15064696-Hematologic Neoplasms,
pubmed-meshheading:15064696-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:15064696-Humans,
pubmed-meshheading:15064696-Male,
pubmed-meshheading:15064696-Melphalan,
pubmed-meshheading:15064696-Middle Aged,
pubmed-meshheading:15064696-Mycophenolic Acid,
pubmed-meshheading:15064696-Opportunistic Infections,
pubmed-meshheading:15064696-Premedication,
pubmed-meshheading:15064696-Prospective Studies,
pubmed-meshheading:15064696-Survival Analysis,
pubmed-meshheading:15064696-Tissue Donors,
pubmed-meshheading:15064696-Transplantation Conditioning,
pubmed-meshheading:15064696-Treatment Outcome,
pubmed-meshheading:15064696-Vidarabine
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
|
|
pubmed:affiliation |
City of Hope National Medical Center, Duarte, CA 91010, USA. robertorodriguez@coh.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
